10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
The European medicines regulator has OK’d a label update for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate), to include people with hyperkalemia on stable hemodialysis. 5 May 2020
A new collaboration targeting rare heart diseases has been formed between California’s BioMarin Pharmaceutical and Swiss gene therapy firm DiNAQOR. 4 May 2020
Privately-held Canadian biotech AbCellera Biologics has received a commitment of up to C$175.6 million ($125 million) in support from the government under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats. 4 May 2020
Research from the non-profit EURORDIS-Rare Diseases alliance shines a light on the impact of the COVID-19 pandemic on people living with rare diseases. 3 May 2020
On May 1, the US Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. 2 May 2020
US pharma major AbbVie closed trading up modest a 0.8% at $82.84 on Friday, despite reporting first-quarter 2020 financials that beat Wall Street predictions. 2 May 2020
The European Medicines Agency (EMA) has announced that it has started a rolling review of data on the use of the drug of the moment – Gilead Sciences’ remdesivir – for the treatment of coronavirus disease (COVID-19). 1 May 2020
Shares in US biotech Seattle Genetics were 8% higher within minutes of trading starting on Friday, following the announcement of the company’s quarterly financial results. 1 May 2020
US biotech giant Amgen late yesterday announced financial results for the first quarter of 2020, showing that revenues increased 11% to $6.2 billion versus the like quarter of 2019. 1 May 2020
Gilead Sciences has reported first quarter revenues of $5.5 billion, beating analysts’ expectations of around $5.45 billion, an increase of 5% compared with the same period in 2019. 1 May 2020
The COVID-19 outbreak is having a terrible impact on patients and frontline medical professionals in many parts of the USA, but that is far from its only effect on the country’s healthcare system. 30 April 2020
French biotech firm Valneva, a pure play vaccine developer, and US pharma giant Pfizer today announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase II clinical studies. 30 April 2020
Vertex Pharmaceuticals’ Trikafta (elexacaftor/tezacaftor/ivacaftor) comes with evidence of providing a major net benefit for patients, but the price tag needs to be massively reduced to align with these benefits. 30 April 2020
Shares of Pharming Group were up almost 4% at 1.32 euros in late afternoon trading today, as the Dutch biotech announced that the European Commission has approved an extension in the indication of Ruconest (conestat alfa). 30 April 2020
UK biotechnology Stabilitech is developing next-generation vaccines and biopharmaceuticals, but is now seeking an investment of £6 million (~$7.5 million) to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19, which, if approved, could be a self-administered capsule. 30 April 2020
The US Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor. 30 April 2020
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) drug to be recommended by the National Institute for Health and Care Excellence (NICE). 29 April 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024